Alpha Centric Advisors LLC Exelixis, Inc. Transaction History

Alpha Centric Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$19.04 - $22.74 $57,120 - $68,220	-3,000 Reduced 9.09%	30,000 $655,000
Q4 2022 Feb 07, 2023	BUY	$14.96 - $17.39 $493,680 - $573,870	33,000 New	33,000 $529,000
Q3 2022 Nov 08, 2022	SELL	$15.68 - $22.27 $595,840 - $846,260	-38,000 Closed	0 $0
Q4 2021 Feb 25, 2022	BUY	$15.84 - $21.88 $237,600 - $328,200	15,000 Added 65.22%	38,000 $695,000
Q3 2021 Mar 09, 2022	BUY	$16.3 - $21.14 $40,750 - $52,850	2,500 Added 12.2%	23,000 $486,000
Q2 2021 Mar 09, 2022	BUY	$17.95 - $25.56 $116,675 - $166,140	6,500 Added 46.43%	20,500 $374,000
Q4 2020 Mar 11, 2022	BUY	$18.39 - $24.8 $202,290 - $272,800	11,000 Added 366.67%	14,000 $281,000
Q3 2020 Mar 11, 2022	SELL	$20.67 - $26.94 $2,067 - $2,694	-100 Reduced 3.23%	3,000 $73,000
Q2 2020 Mar 11, 2022	BUY	$16.46 - $27.42 $51,026 - $85,002	3,100 New	3,100 $74,000

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.